Following the pilot study on sodium benzoate for the treatment of cognitive function of early-phase AD (Lin et al., 2014), the current study further supports that DAO could serve as a novel target of drug development for early stages of cognitive decline. The gene discussed is DAO; the disease is Alzheimer disease.